The Food and Drug Administration Friday issued warning letters to all three duodenoscope manufacturers for failing to comply with a 2015 order to conduct postmarket surveillance studies to determine whether health care facilities are able to properly clean and disinfect the devices. “The FDA has taken important steps to improve the reprocessing of duodenoscopes, and we’ve seen a reduction in reports of patient infections, but we need the required postmarket studies to determine whether these measures are being properly implemented in real-world clinical settings and whether we need to take additional action to further improve the safety of these devices,” said Jeff Shuren, M.D., director of the FDA’s Center for Devices and Radiological Health. “We expect these device manufacturers to meet their study obligations to ensure patient safety.” The letters were sent to Olympus, Fujifilm and Pentax, who are expected to submit a plan by March 24 outlining how study milestones will be achieved.

Related News Articles

Perspective
Public
Hospitals and health systems across the country vary in size, as well as the types of services and specialties they offer. They also offer many different…
Headline
The AHA Aug. 7 launched a new webpage, Reducing Disparities in Health Outcomes, featuring new and familiar resources for members and their communities. As part…
Headline
Nell Buhlman, chief administrative officer and head of strategy at Press Ganey, and Chris DeRienzo, M.D., AHA chief physician executive, explore the data-…
Perspective
Public
The 2025 AHA Leadership Summit wrapped up on July 22, and as always, it was energizing and inspiring to connect with so many talented and dedicated people…
Headline
The AHA July 24 announced it is collaborating with health care technology leader Epic to help hospitals adopt tools that support the early detection and…
Headline
Carolyn Bogard, DNP, R.N., director of care coordination and palliative care at El Camino Health, talks about her system’s use of data to harness the passion…